{"id":441936,"date":"2021-02-23T09:03:16","date_gmt":"2021-02-23T14:03:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=441936"},"modified":"2021-02-23T09:03:16","modified_gmt":"2021-02-23T14:03:16","slug":"imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/","title":{"rendered":"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>Clinical validation of high throughput assay that provides numeric results (titer) of neutralizing antibodies<\/em><br \/>\n          \n        <\/li>\n<li>\n          <em>Former COVID-19 patients, in a small preliminary sample set, saw marked decline in neutralizing antibodies within six months<\/em>\n        <\/li>\n<li>\n          <em>Assay shows no guarantee that severe disease results in higher levels of antibody protection<\/em>\n        <\/li>\n<\/ul>\n<p>ROCHESTER, Minn., Feb.  23, 2021  (GLOBE NEWSWIRE) &#8212; Imanis Life Sciences (\u201cImanis\u201d or \u201cThe Company\u201d), in collaboration with <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WLhMFW1CetQa7uiAniI0tlknwJnL1WstaNMr-9LUvVzfD1mVSZNME3ouiLyFScpoDEv9rxEt8LlpIZrtOS7law==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Vyriad, Inc<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oCLzvRAaPBOVtf_tl_A8e03rkcmcNkq9npFC8UmetMf5_zXTztxa9PkJYnQQH9ss\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">.<\/a><\/u> and <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fV6Bs3dW2h2b0ELCCpyooNiKqzKUyyno2CywI_Xv6iAoHZIGwtdaFj55-8Sv9unP_Cwj2Hr9r71KG8XJeiI5kA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Regeneron<\/a><\/u>, today announced data from its latest improved<u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SVZfgKa7T_4S6MqUH_q6oyqM7ZjZICjG-xbZAMHZXwK4ACiV3ao4_ItsbdXjyrEAlbjCNb4miQJ00dTt_x304w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">IMMUNO-COV<\/a><\/u><sup>TM<\/sup> test, an assay for the quantitative measure of SARS-CoV-2 (COVID-19) neutralizing antibodies. The manuscript is available on <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kWitLW2GN-BNOzx-ZO_21Zz-AJ1LNtH2ohquTo_SXl_lV0gNgFSmG7OcFZe-aNOzXmt2KxaW2W70qLWEqaC7WRr6kU0x2RUUKydW-1ZgtNiKu0jNLweJqp-jrUL0PxvP\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">med<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xe8AcypKld2CN6_NfnKuSTXJjBSwpqPfJo73k1KV8yYZ-TS2dnphGBQUiKzpB7GWYM-z1nPu_166qq_rvQX3pg2-QcBLxkknrP32fejyYHxWPZ-CLBS3lVF2gd2A7KWS\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Rxiv<\/a><\/u> and has been submitted for additional publication following scientific peer review.<\/p>\n<p>Data acquired from a small initial cohort showed that neutralizing antibodies declined at least 50% within six months in nearly all individuals recovering from COVID-19 infection. Samples from this small test group were first secured in April and then again in October and tested via IMMUNO-COV, the first scalable, quantitative virus neutralizing antibody test for COVID-19. The results correlated closely with those acquired by plaque reduction neutralization test (PRNT), which remains the <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RXcStxScbEYN4Gia6Afn4UHteRSpmObc4IUe4_zY3m9HgM7U88owkdSbfFoDA4rZx-kei1AAxyPu0e2xZHVaz8Z06enWu6qvLpzZFH5uXatP33uNZlZg3xV6ljo83lIgT8L-NiV4g_yHn3cstamdoSFXuiHxgSSR6F_EnB5MblhumTuXSr43YXVVGPkzJwa2\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">gold standard for serological testing and determining immune protection<\/a><\/u>. A scalable, clinical test for measuring neutralizing antibody titers is critical for large population studies of COVID-19 immunity. Imanis, with its IMMUNO-COV assay, plans to test samples from larger cohorts to continue to track the rate of neutralizing antibody decline in both recovered patients and inoculated individuals.<\/p>\n<p>\u201cIMMUNO-COV was developed to address the unmet and urgent need of a deeper understanding around the spread of COVID-19,\u201d said Michael Herbert, Chief Commercial Officer at Imanis. \u201cPRNT is the gold standard of quantitative assays, which is why we ensured our results correlated; however, it is not widely scalable for surveillance of COVID-19 protection and vaccine efficacy. We are proud to be able to offer a solution to this gap through IMMUNO-COV, which is both accurate and widely scalable.\u201d<\/p>\n<p>As part of the clinical trial, participants were asked to report the severity of their COVID-19 symptoms in order to compare disease severity to the number of SARS-CoV-2 neutralizing antibodies detected by the assay. While the general trend supported the current notion that people with more severe cases of COVID-19 are more likely to generate higher levels of neutralizing antibodies, the assay showed there is no guarantee that severe disease results in higher levels of antibody protection. Regardless of disease severity, individuals develop a wide range of neutralizing antibody titers.<\/p>\n<p>\u201cNeutralizing antibodies are key determinants of protection from future infection,\u201d said Rianna Vandergaast, Ph.D., Principal Scientist at Imanis. \u201cThe ability to monitor neutralizing antibody titers could not only help us determine the duration of immunity, but also better understand the timeline required between vaccine inoculation and boosters.\u201d<\/p>\n<p>\u201cThese results continue to support the value and validity of IMMUNO-COV,\u201d said Stephen Russell, M.D., Ph.D., CEO and co-founder of Imanis. \u201cWe are encouraged by the continued possibilities of the test to help answer many of the burning questions around COVID-19.\u201d<\/p>\n<p>\n        <strong>About Imanis Life Sciences<\/strong><br \/>\n        <br \/>Imanis Life Sciences has an unwavering commitment to the advancement of science. For many companies, profitability rules decision making. But at Imanis, leading scientific breakthroughs is the primary focus. We are about making a difference in the world by putting people in a better position than they were yesterday. We strive to do this by being a leader in laboratory assays and research services to accelerate the development of a broad range of next-generation therapies. Imanis Life Sciences is located in Rochester, Minnesota. For more information, visit <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V0XGFQWGJbgb9fBAZs0v9iZAs5CnBADlZglCr_cSsa1MUMIVGeaEkqaE8Hvuie4zXEe37H89X9nuWP_osJd0AbyKsBdJ53KvYqsc3z9pArY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/imanis-immunocov.com<\/a><\/u>.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Media Contact<\/strong><br \/>\n            <br \/>Will Johnson<br \/>Antenna Group<br \/><u><a href=\"mailto:imanis@antennagroup.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">imanis@antennagroup.com<\/a><\/u><br \/>(201) 465-8019\u00a0<\/td>\n<td style=\"vertical-align: top\">\n            <strong>Company Inquiries<\/strong><br \/>\n            <br \/>Michael Herbert<br \/>Chief Commercial Officer <br \/>Imanis Life Sciences<br \/><u><a href=\"mailto:Herbert.michael@imanislife.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Herbert.michael@imanislife.com<\/a><\/u><br \/>(612) 309-7801<\/td>\n<\/tr>\n<\/table>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/69a91c0e-7c65-4b01-9870-9f7bdfffeb48\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical validation of high throughput assay that provides numeric results (titer) of neutralizing antibodies Former COVID-19 patients, in a small preliminary sample set, saw marked decline in neutralizing antibodies within six months Assay shows no guarantee that severe disease results in higher levels of antibody protection ROCHESTER, Minn., Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Imanis Life Sciences (\u201cImanis\u201d or \u201cThe Company\u201d), in collaboration with Vyriad, Inc. and Regeneron, today announced data from its latest improvedIMMUNO-COVTM test, an assay for the quantitative measure of SARS-CoV-2 (COVID-19) neutralizing antibodies. The manuscript is available on medRxiv and has been submitted for additional publication following scientific peer review. Data acquired from a small initial cohort showed that neutralizing antibodies declined at least 50% within &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-441936","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Clinical validation of high throughput assay that provides numeric results (titer) of neutralizing antibodies Former COVID-19 patients, in a small preliminary sample set, saw marked decline in neutralizing antibodies within six months Assay shows no guarantee that severe disease results in higher levels of antibody protection ROCHESTER, Minn., Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Imanis Life Sciences (\u201cImanis\u201d or \u201cThe Company\u201d), in collaboration with Vyriad, Inc. and Regeneron, today announced data from its latest improvedIMMUNO-COVTM test, an assay for the quantitative measure of SARS-CoV-2 (COVID-19) neutralizing antibodies. The manuscript is available on medRxiv and has been submitted for additional publication following scientific peer review. Data acquired from a small initial cohort showed that neutralizing antibodies declined at least 50% within &hellip; Continue reading &quot;Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-23T14:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies\",\"datePublished\":\"2021-02-23T14:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/\"},\"wordCount\":622,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/\",\"name\":\"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=\",\"datePublished\":\"2021-02-23T14:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/","og_locale":"en_US","og_type":"article","og_title":"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies - Market Newsdesk","og_description":"Clinical validation of high throughput assay that provides numeric results (titer) of neutralizing antibodies Former COVID-19 patients, in a small preliminary sample set, saw marked decline in neutralizing antibodies within six months Assay shows no guarantee that severe disease results in higher levels of antibody protection ROCHESTER, Minn., Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Imanis Life Sciences (\u201cImanis\u201d or \u201cThe Company\u201d), in collaboration with Vyriad, Inc. and Regeneron, today announced data from its latest improvedIMMUNO-COVTM test, an assay for the quantitative measure of SARS-CoV-2 (COVID-19) neutralizing antibodies. The manuscript is available on medRxiv and has been submitted for additional publication following scientific peer review. Data acquired from a small initial cohort showed that neutralizing antibodies declined at least 50% within &hellip; Continue reading \"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-23T14:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies","datePublished":"2021-02-23T14:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/"},"wordCount":622,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/","name":"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=","datePublished":"2021-02-23T14:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzIxNyMzOTg4NDc3IzIyMDUxMjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imanis-life-sciences-announces-new-data-from-clinical-assay-measuring-sars-cov-2-neutralizing-antibodies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=441936"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441936\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=441936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=441936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=441936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}